Status:
COMPLETED
A Multinational Phase III Study of CS-8958 (MARVEL)
Lead Sponsor:
Daiichi Sankyo Co., Ltd.
Conditions:
Influenza, Human
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
The primary objective of this study is to confirm the efficacy of CS-8958 administered as a single inhaled low dose or single inhaled high dose by showing non-inferiority to oseltamivir phosphate usin...
Eligibility Criteria
Inclusion
- Clinical diagnosis of influenza
- Axillary temperature of \> or = to 37.5 degrees C
Exclusion
- Infection by bacteria species and/or virus other than influenza virus
- Chronic respiratory disease
- Renal dysfunction
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
1002 Patients enrolled
Trial Details
Trial ID
NCT00803595
Start Date
November 1 2008
End Date
June 1 2009
Last Update
January 9 2019
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Hong Kong, China
2
Tokyo, Japan
3
Seoul, South Korea
4
Taipei, Taiwan